Bio-Techne Corp(TECH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | 62.75 | EPS (ttm) | 1.16 | Insider Own | 0.55% | Shs Outstand | 156.1M | Perf Week | 0.28% |
| Market Cap | 11.40B | Forward P/E | 30.58 | EPS next Y | 16.89% | Insider Trans | -0.76% | Shs Float | 155.9M | Perf Month | 0.11% |
| Enterprise Value | 11.42B | PEG | 3.83 | EPS next Q | 0.44 | Inst Own | 113.33% | Short Float | 4.74% | Perf Quarter | 0.86% |
| Income | 0.18B | P/S | 9.38 | EPS this Y | 5.35% | Inst Trans | -2.9% | Short Ratio | 2.44 | Perf Half Y | 31.9% |
| Sales | 1.22B | P/B | 5.38 | EPS next 5Y | 7.98% | ROA | 6.95% | Short Interest | 7.39M | Perf YTD | 23.6% |
| Book/sh | 13.51 | P/C | 43.06 | EPS past 3/5Y | -13.05% 5.97% | ROE | 9.03% | 52W High | 0% ($72.69) | Perf Year | 10.3% |
| Cash/sh | 1.69 | P/FCF | 43.31 | Sales past 3/5Y | 2.25% 5.47% | ROIC | 7.63% | 52W Low | 68.28% ($43.19) | Perf 3Y | 18.18% |
| Dividend Est. | $0.32 (0.44%) | EV/EBITDA | 30.89 | EPS Y/Y TTM | 152.71% | Gross Margin | 66.03% | Volatility(W/M) | 0.19% 0.19% | Perf 5Y | -43.95% |
| Dividend TTM | 0.32 | EV/Sales | 9.4 | Sales Y/Y TTM | -0.38% | Oper. Margin | 22.42% | ATR (14) | 0.15 | Perf 10Y | 186.46% |
| Dividend Ex-Date | 2026/8/24 | Quick Ratio | 3.35 | EPS Q/Q | 404.46% | Profit Margin | 14.97% | RSI (14) | 60.63 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.55 | Sales Q/Q | 1.33% | SMA20 | 0.24% ($72.52) | Beta | 1.29 | Target Price | $73 |
| Payout | 27.63% | Debt/Eq | 0.14 | Earnings | 2026/8/12 | SMA50 | 0.36% ($72.43) | Rel Volume | 0.92 | Prev Close | $72.55 |
| Employees | 3000 | LT Debt/Eq | 0.13 | EPS/Sales Surpr. | 0.12% 2.09% | SMA200 | 15.31% ($63.04) | Avg Volume(3M) | 3.03M | Price | $72.69 |
| IPO | 1989/2/9 | Option/Short | Yes/Yes | Trades | 12042 | Volume | 2,798,531 | Change | 0.19% |
🔬 A healthcare tools company that supplies high-purity proteins, antibodies, reagents, and analytical instruments used in life sciences research and clinical diagnostics. It covers recombinant proteins, antibodies, immunoassay products, protein analysis platforms, and diagnostic products, making it a life sciences tools name whose earnings are tied to research and development and diagnostics demand.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded about as much as usual. That is 92% of its average volume.
TECH earns at a steady pace
Of every $100 in sales, $22.42 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +5.3% this year.
Tap to view numbers
However, it looks expensive
For a company expected to earn $100 next year, you would pay $3,058. Peers typically go for $2,295. It is about in line with its own 5-year average.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -44.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
The dividend is on the small side
Pays 0.44% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 113.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
PBE Invesco Biotechnology & Genome ETF 0.04% 
FBT First Trust NYSE Arca Biotechnology Index Fund 0.03% 
GNOM Global X Genomics & Biotechnology ETF 0.03% 
FMED Fidelity Disruptive Medicine ETF 0.02% 
RSPH Invesco S&P 500 Equal Weight Health Care ETF 0.02% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
VGT Vanguard Information Technology ETF 147.5B 
XLK State Street Technology Select Sector SPDR ETF 121.0B 
IYW iShares U.S. Technology ETF 24.3B 
FTEC Fidelity MSCI Information Technology Index ETF 21.1B 
DRAM Roundhill Memory ETF 18.5B It ranks #20 of 594 in the industry
Based on market cap of $11B.
FAQ
What kind of company is TECH?
TECH belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TECH?
The market cap of TECH is approximately $11.4B, ranking 838 within its sector.
Does TECH pay dividends?
TECH has a dividend yield of approximately 0.44%, with an annual dividend of $0.32.
What is the P/E ratio of TECH?
TECH has a P/E ratio of approximately 62.8x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for TECH?
TECH has recorded a 52-week high of $72.69 and a low of $43.19.
